SCHEMBL1970885

SCHEMBL1970885

NC(=O)CC[C@H](N)C(=O)c1ccc([C](c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 2/20 0.47
PMP22 Q01453 2/20 0.47
KMT2A Q03164 2/20 0.47
ALOX15 P16050 1/20 0.47
MDM2 Q00987 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.38
MAPT P10636 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
PARP1 P09874 1/20 0.38
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALDH1A1 P00352 2/20 0.37
HTT P42858 2/20 0.37
RAB9A P51151 2/20 0.37
ATM Q13315 2/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29634956 0.93 BLM (0.53) BLMPMP22KMT2AALOX15MDM2
SCHEMBL5057390 0.83 MDM2 (0.41) BLMPMP22MDM2L3MBTL1MAPT
SCHEMBL1969120 0.83 L3MBTL1 (0.41) BLMPMP22MDM2L3MBTL1MAPT
SCHEMBL28121840 0.82 KMT2A (0.42) BLMPMP22KMT2AALOX15MDM2
SCHEMBL4658683 0.81 BLM (0.47) BLMPMP22KMT2AALOX15L3MBTL1
SCHEMBL4658680 0.81 BLM (0.47) BLMPMP22KMT2AALOX15L3MBTL1
SCHEMBL12698767 0.81 CYP1A2 (0.52) MDM2L3MBTL1MAPTTDP1TSHR
SCHEMBL5495906 0.80 MDM2 (0.43) BLMPMP22KMT2AALOX15MDM2
SCHEMBL4751891 0.78 ANPEP (0.44) MDM2L3MBTL1TDP1LMNACES2
SCHEMBL29029660 0.78 MDM2 (0.53) BLMPMP22KMT2AALOX15MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2177530-B1 Octapeptide having antiangiogenic activity ABBOTT LAB (US) 2011-06-22 EP disclosed
EP-2177530-A1 Octapeptide having antiangiogenic activity Abbott Laboratories (US) 2010-04-21 EP disclosed
US-20080071062-A1 TETRA-, PENTA-, HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY HAVIV FORTUNA 2008-03-20 US disclosed
US-20070167376-A1 Hexa-, Hepta-, and Octapeptides Having Antiangiogenic Activity HAVIV FORTUNA 2007-07-19 US disclosed
US-7169888-B2 Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity ABBOTT LABORATORIES (US) 2007-01-30 US disclosed
US-7122625-B2 Hexa-, hepta-, and octapeptides having antiangiogenic activity ABBOTT LABORATORIES (US) 2006-10-17 US disclosed
US-20060194737-A1 Hepta-, octa-and nonapeptides having antiangiogenic activity HAVIV FORTUNA 2006-08-31 US disclosed
US-7067490-B2 Hepta-, Octa-and nonapeptides having antiangiogenic activity ABBOTT LABORATORIES (US) 2006-06-27 US disclosed
US-7037897-B2 TRI-, TETRA-, and penta-peptides having antiangiogenic activity ABBOTT LABORATORIES (US) 2006-05-02 US disclosed
US-7001984-B2 Di-, tri-, and tetra-peptides having antiangiogenic activity ABBOTT LABORATORIES (US) 2006-02-21 US disclosed
EP-1232183-B1 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LAB (US) 2006-01-18 EP disclosed
US-20050215484-A1 Di-, tri-, and tetra-peptides having antiangiogenic activity HAVIV FORTUNA 2005-09-29 US disclosed
US-6777535-B1 USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS ABBOTT LABORATORIES 2004-08-17 US disclosed
US-6753408-B1 DRUGS USED FOR THERAPY ABBVIE INC. 2004-06-22 US disclosed